Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07854262 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

EFFECT OF ESWT ON BREAST-CANCER RELATED LYMPHEDEMA

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 2, 2026 (before its estimated October 14, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The aim of this study is to evaluate the effectiveness of extracorporeal shock wave therapy (ESWT) combined with complete decongestive therapy (CDT) compared with CDT alone in patients with breast cancer-related lymphedema. Female patients with unilateral Stage II upper-extremity lymphedema related to breast cancer will be included. Participants will receive either complete decongestive therapy alone or complete decongestive therapy combined with extracorporeal shock wave therapy. Clinical outcomes will be evaluated before treatment, immediately after treatment, and at 1 and 3 months after treatment. Primary outcomes will include limb circumference difference, volumetric measurements, and ultrasonographic assessment of skin and subcutaneous tissue thickness. Secondary outcomes will include upper-extremity function, quality of life, and pain.
Trial Details
NCT Number NCT07854262
Lead Sponsor Ankara City Hospital Bilkent
Conditions
(from sponsor)		 Breast Cancer Related Lymphedema
Related terms Breast Cancer Lymphedema
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov